Activation of TREK-1, but Not TREK-2, Channel by Mood Stabilizers
Abstract
:1. Introduction
2. Results
2.1. Effect of Antidepressants and Antipsychotics on TREK-1 and TREK-2 Current
2.2. Effect of Mood Stabilizers on TREK-1 and TREK-2 Current
2.3. Alteration in TREK Protein Expression by Antidepressants and Mood Stabilizers in Hippocampal Neuronal Cell Line
3. Discussion
3.1. TREK-1 Channel as a New Target for Mood Disorder
3.2. Mood Stabilizers Can Discriminate TREK-1 from TREK-2, In Vitro
4. Materials and Methods
4.1. Cell Culture and Transfection of HEK-293 Cells
4.2. Electrophysiological Studies
4.3. Western Blot Analysis
4.4. Chemicals
4.5. Data Analysis and Statistics
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
Abbreviations
5-HT | 5-Hydroxytryptamine |
LiCl | Lithium chloride |
TREK | TWIK-related K+ |
K2P | Two-pore domain K+ channel |
References
- Kennard, L.E.; Chumbley, J.R.; Ranatunga, K.M.; Armstrong, S.J.; Veale, E.L.; Mathie, A. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br. J. Pharmacol. 2005, 144, 821–829. [Google Scholar] [CrossRef] [PubMed]
- Thummler, S.; Duprat, F.; Lazdunski, M. Antipsychotics inhibit TREK but not TRAAK channels. Biochem. Biophys. Res. Commun. 2007, 354, 284–289. [Google Scholar] [CrossRef] [PubMed]
- Heurteaux, C.; Lucas, G.; Guy, N.; El Yacoubi, M.; Thummler, S.; Peng, X.D.; Noble, F.; Blondeau, N.; Widmann, C.; Borsotto, M.; et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat. Neurosci. 2006, 9, 1134–1141. [Google Scholar] [CrossRef] [PubMed]
- Hur, C.G.; Kim, E.J.; Cho, S.K.; Cho, Y.W.; Yoon, S.Y.; Tak, H.M.; Kim, C.W.; Choe, C.; Han, J.; Kang, D. K+ efflux through two-pore domain K+ channels is required for mouse embryonic development. Reproduction 2012, 143, 625–636. [Google Scholar] [CrossRef] [PubMed]
- Cryan, J.F.; Slattery, D.A. Animal models of mood disorders: Recent developments. Curr. Opin. Psychiatry 2007, 20. [Google Scholar] [CrossRef] [PubMed]
- Maruyama, Y.; Yamada, M. TREK-1: A potential target for novel antidepressants. Nihon Shinkei Seishin Yakurigaku Zasshi 2007, 27, 147–151. [Google Scholar] [PubMed]
- Kim, D. Physiology and pharmacology of two-pore domain potassium channels. Curr. Pharm. Des. 2005, 11, 2717–2736. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Bijur, G.N.; Jope, R.S. Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord. 2002, 4, 137–144. [Google Scholar] [CrossRef] [PubMed]
- Keck, P.E., Jr.; McElroy, S.L.; Strakowski, S.M. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry 1998, 59, 74–81. [Google Scholar] [PubMed]
- Bown, C.D.; Wang, J.F.; Young, L.T. Attenuation of N-methyl-d-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience 2003, 117, 949–955. [Google Scholar] [CrossRef]
- Li, R.; El-Mallahk, R.S. A novel evidence of different mechanisms of lithium and valproate neuroprotective action on human SY5Y neuroblastoma cells: Caspase-3 dependency. Neurosci. Lett. 2000, 294, 147–150. [Google Scholar] [CrossRef]
- Tanabe, M.; Umeda, M.; Honda, M.; Ono, H. Phenytoin and carbamazepine delay the initial depression of the population spike upon exposure to in vitro ischemia and promote its post-ischemic functional recovery in rat hippocampal slices. Eur. J. Pharmacol. 2006, 553, 104–108. [Google Scholar] [CrossRef] [PubMed]
- Post, R.M.; Denicoff, K.D.; Frye, M.A.; Dunn, R.T.; Leverich, G.S.; Osuch, E.; Speer, A. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998, 38, 152–166. [Google Scholar] [CrossRef] [PubMed]
- Calabrese, J.R.; Bowden, C.L.; Sachs, G.S.; Ascher, J.A.; Monaghan, E.; Rudd, G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 1999, 60, 79–88. [Google Scholar] [CrossRef] [PubMed]
- Frye, M.A.; Ketter, T.A.; Kimbrell, T.A.; Dunn, R.T.; Speer, A.M.; Osuch, E.A.; Luckenbaugh, D.A.; Cora-Ocatelli, G.; Leverich, G.S.; Post, R.M. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol. 2000, 20, 607–614. [Google Scholar] [CrossRef] [PubMed]
- Bowden, C.L.; Calabrese, J.R.; McElroy, S.L.; Rhodes, L.J.; Keck, P.E., Jr.; Cookson, J.; Anderson, J.; Bolden-Watson, C.; Ascher, J.; Monaghan, E.; et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol. Psychiatry 1999, 45, 953–958. [Google Scholar] [CrossRef]
- Thomas, D.; Plant, L.D.; Wilkens, C.M.; McCrossan, Z.A.; Goldstein, S.A. Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium. Neuron 2008, 58, 859–870. [Google Scholar] [CrossRef] [PubMed]
- Bolo, N.R.; Hode, Y.; Nedelec, J.F.; Laine, E.; Wagner, G.; Macher, J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000, 23, 428–438. [Google Scholar] [CrossRef]
- Patel, A.J.; Honore, E.; Maingret, F.; Lesage, F.; Fink, M.; Duprat, F.; Lazdunski, M. A mammalian two pore domain mechano-gated S-like K+ channel. EMBO J. 1998, 17, 4283–4290. [Google Scholar] [CrossRef] [PubMed]
- Kim, D. Fatty acid-sensitive two-pore domain K+ channels. Trends Pharmacol. Sci. 2003, 24, 648–654. [Google Scholar] [CrossRef] [PubMed]
- Kang, D.; Choe, C.; Kim, D. Thermosensitivity of the two-pore domain K+ channels TREK-2 and TRAAK. J. Physiol. 2005, 564, 103–116. [Google Scholar] [CrossRef] [PubMed]
- Maingret, F.; Lauritzen, I.; Patel, A.J.; Heurteaux, C.; Reyes, R.; Lesage, F.; Lazdunski, M.; Honore, E. TREK-1 is a heat-activated background K+ channel. EMBO J. 2000, 19, 2483–2491. [Google Scholar] [CrossRef] [PubMed]
- Maingret, F.; Patel, A.J.; Lesage, F.; Lazdunski, M.; Honore, E. Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel. J. Biol. Chem. 1999, 274, 26691–26696. [Google Scholar] [CrossRef] [PubMed]
- Chemin, J.; Girard, C.; Duprat, F.; Lesage, F.; Romey, G.; Lazdunski, M. Mechanisms underlying excitatory effects of group I metabotropic glutamate receptors via inhibition of 2P domain K+ channels. EMBO J. 2003, 22, 5403–5411. [Google Scholar] [CrossRef] [PubMed]
- Kang, D.; Han, J.; Kim, D. Mechanism of Inhibition of TREK-2 (K2P10.1) by the Gq-coupled M3 muscarinic receptor. Am. J. Physiol. Cell Physiol. 2006. [Google Scholar] [CrossRef] [PubMed]
- Blin, S.; Ben Soussia, I.; Kim, E.J.; Brau, F.; Kang, D.; Lesage, F.; Bichet, D. Mixing and matching TREK/TRAAK subunits generate heterodimeric K2P channels with unique properties. Proc. Natl. Acad. Sci. USA 2016, 113, 4200–4205. [Google Scholar] [CrossRef] [PubMed]
- Levitz, J.; Royal, P.; Comoglio, Y.; Wdziekonski, B.; Schaub, S.; Clemens, D.M.; Isacoff, E.Y.; Sandoz, G. Heterodimerization within the TREK channel subfamily produces a diverse family of highly regulated potassium channels. Proc. Natl. Acad. Sci. USA 2016, 113, 4194–4199. [Google Scholar] [CrossRef] [PubMed]
- Braun, G.; Lengyel, M.; Enyedi, P.; Czirjak, G. Differential sensitivity of TREK-1, TREK-2 and TRAAK background potassium channels to the polycationic dye ruthenium red. Br. J. Pharmacol. 2015, 172, 1728–1738. [Google Scholar] [CrossRef] [PubMed]
- Koukopoulos, A.; Ghaemi, S.N. The primacy of mania: A reconsideration of mood disorders. Eur. Psychiatry 2009, 24, 125–134. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, E.-J.; Lee, D.K.; Hong, S.-G.; Han, J.; Kang, D. Activation of TREK-1, but Not TREK-2, Channel by Mood Stabilizers. Int. J. Mol. Sci. 2017, 18, 2460. https://doi.org/10.3390/ijms18112460
Kim E-J, Lee DK, Hong S-G, Han J, Kang D. Activation of TREK-1, but Not TREK-2, Channel by Mood Stabilizers. International Journal of Molecular Sciences. 2017; 18(11):2460. https://doi.org/10.3390/ijms18112460
Chicago/Turabian StyleKim, Eun-Jin, Dong Kun Lee, Seong-Geun Hong, Jaehee Han, and Dawon Kang. 2017. "Activation of TREK-1, but Not TREK-2, Channel by Mood Stabilizers" International Journal of Molecular Sciences 18, no. 11: 2460. https://doi.org/10.3390/ijms18112460